# US 2025/0375519 A1 · Materials And Methods Of Treating MHC-1-Opathy Risk Haplotypes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375519 A1
- Document ID: US20250375519A1
- Status: Published application
- Kind: A1
- Application number: 19/249,070
- Filed: 2025-06-25
- Published: 2025-12-11
- Earliest claimed: 2021-04-07
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Sahar Gelfman; Ann Ligocki; Giovanni Coppola; Aris Baras; Arden Moscati; Eli A. Stahl; Jack A. Kosmicki; Manuel Allen Revez Ferreira; Carmelo Romano
- Web page: https://patentgrep.com/patent/US20250375519A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- C12N 9/485: {Exopeptidases (3.4.11-3.4.19)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C07K 16/40: against enzymes
- C12Q 1/00: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (measuring or testing apparatus with condition measuring or sensing means, e.g. colony counters, C12M1/34); Compositions therefor; Processes of preparing such compositions
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides methods of treating subjects having an immune disorder by administering to the subject a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor in combination with an HLA-A29 or HLA-B27 inhibitory nucleic acid molecule.

## Claims

### Claim 1

A method of treating a subject having an immune disorder, the method comprising administering to the subject an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitory nucleic acid molecule and: i) an HLA-A29 inhibitor inhibitory nucleic acid molecule and/or ii) an HLA-B27 inhibitory nucleic acid molecule.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the immune disorder is an MHC-I-opathy.

### Claim at position 3

3-10. (canceled)

### Claim 11 (depends on 2)

The method according to claim 2, wherein the MHC-I-opathy is Ankylosing Spondylitis (AS), and the method comprises administering the ERAP2 inhibitor inhibitory nucleic acid molecule and the HLA-B27 inhibitory nucleic acid molecule to the subject.

### Claim 12 (depends on 11)

The method according to claim 11, the method further comprising detecting the presence or absence of an HLA-B27 allele in a biological sample obtained from the subject.

### Claim 13 (depends on 12)

The method according to claim 12, the method further comprising determining whether the subject has one or two copies of an HLA-B27 allele.

### Claim at position 7

14-15. (canceled)

### Claim 16 (depends on 11)

The method according to claim 11, wherein the HLA-B27 inhibitory nucleic acid molecule comprises an HLA-B27 antisense nucleic acid molecule, an HLA-B27 small interfering RNA (siRNA), or an HLA-B27 short hairpin RNA that hybridizes to an HLA-B27 mRNA.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the HLA-B27 antisense nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 2788-3132.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the HLA-B27 siRNA molecule comprises a sense strand and a corresponding antisense strand selected from the group consisting of SEQ ID NOs: 3133-3870.

### Claim 19 (depends on 2)

The method according to claim 2, wherein the MHC-I-opathy is psoriasis and the subject also has uveitis, and the method comprises administering the ERAP2 nucleic acid molecule and the HLA-B27 inhibitory nucleic acid molecule to the subject.

### Claim at position 12

20-26. (canceled)

### Claim 27 (depends on 2)

The method according to claim 2, wherein the MHC-I-opathy is Juvenile Idiopathic Arthritis (JIA), and the method comprises administering the ERAP2 inhibitor inhibitory nucleic acid molecule and the HLA-B27 inhibitory nucleic acid molecule to the subject.

### Claim at position 14

28-35. (canceled)

### Claim 36 (depends on 1)

The method according to claim 1, wherein the ERAP2 inhibitory nucleic acid molecule comprises an ERAP2 antisense nucleic acid molecule, an ERAP2 small interfering RNA (siRNA), or an ERAP2 short hairpin RNA that hybridizes to ERAP2 mRNA.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the ERAP2 antisense nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-858.

### Claim 38 (depends on 36)

The method according to claim 36, wherein the ERAP2 siRNA molecule comprises a sense strand and a corresponding antisense strand selected from the group consisting of SEQ ID NOs: 859-2748.

### Claim at position 18

39-43. (canceled)

### Claim 44

A method of treating a subject having an MHC-I-opathy, the method comprising:
performing or having performed an assay on a biological sample from the subject to determine whether the subject comprises:
i) an HLA-A29 allele and/or an HLA-B27 allele; and
ii) a functional Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) protein or a nucleic acid molecule encoding a functional ERAP2 protein; and
administering to the subject a therapeutically effective amount of an ERAP2 inhibitor inhibitory nucleic acid molecule and an HLA-A29 inhibitor inhibitory nucleic acid molecule to the subject having the functional ERAP2 protein or the nucleic acid molecule encoding a functional ERAP2 protein, and having the HLA-A29 allele; or
administering to the subject a therapeutically effective amount of an ERAP2 inhibitory nucleic acid molecule and an HLA-B27 inhibitory nucleic acid molecule to the subject having the functional ERAP2 protein or the nucleic acid molecule encoding a functional ERAP2 protein, and having the HLA-B27 allele; wherein the presence of both: i) the HLA-A29 allele and/or the HLA-B27 allele, and ii) the functional ERAP2 protein or the nucleic acid molecule encoding a functional ERAP2 protein, indicates that the subject is a candidate for treating the MHC-I-opathy by inhibiting ERAP2.

### Claim 45 (depends on 44)

The method according to claim 44, wherein the MHC-I-opathy is Birdshot Chorioretinopathy (BSCR), and the method comprises administering the ERAP2 inhibitory nucleic acid molecule and the HLA-A29 inhibitory nucleic acid molecule to the subject.

### Claim at position 21

46-49. (canceled)

### Claim 50 (depends on 44)

The method according to claim 44, wherein the HLA-A29 inhibitory nucleic acid molecule comprises an HLA-A29 antisense nucleic acid molecule, an HLA-A29 small interfering RNA (siRNA), or an HLA-A29 short hairpin RNA that hybridizes to an HLA-A29 mRNA.

### Claim 51 (depends on 50)

The method according to claim 50, wherein the HLA-A29 antisense nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 3871-4145.

### Claim 52 (depends on 50)

The method according to claim 50, wherein the HLA-A29 siRNA molecule comprises a sense strand and a corresponding antisense strand selected from the group consisting of SEQ ID NOs: 4146-4755.

### Claim 53 (depends on 44)

The method according to claim 44, wherein the MHC-I-opathy is Ankylosing Spondylitis (AS), and the method comprises administering the ERAP2 inhibitory nucleic acid molecule and the HLA-B27 inhibitory nucleic acid molecule to the subject.

### Claim at position 26

54-60. (canceled)

### Claim 61 (depends on 44)

The method according to claim 44, wherein the MHC-I-opathy is psoriasis and the subject also has uveitis, and the method comprises administering the ERAP2 inhibitor inhibitory nucleic acid molecule and the HLA-B27 inhibitory nucleic acid molecule to the subject.

### Claim at position 28

62-68. (canceled)

### Claim 69 (depends on 44)

The method according to claim 44, wherein the MHC-I-opathy is Juvenile Idiopathic Arthritis (JIA), and the method comprises administering the ERAP2 inhibitor inhibitory nucleic acid molecule and the HLA-B27 inhibitor inhibitory nucleic acid molecule to the subject.

### Claim at position 30

70-77. (canceled)

### Claim 78 (depends on 44)

The method according to claim 44, wherein the ERAP2 inhibitory nucleic acid molecule comprises an ERAP2 antisense nucleic acid molecule, an ERAP2 small interfering RNA (siRNA), or an ERAP2 short hairpin RNA that hybridizes to ERAP2 mRNA.

### Claim 79 (depends on 78)

The method according to claim 78, wherein the ERAP2 antisense nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-858.

### Claim 80 (depends on 78)

The method according to claim 78, wherein the ERAP2 siRNA molecule comprises a sense strand and a corresponding antisense strand selected from the group consisting of SEQ ID NOs: 859-2748.

### Claim at position 34

81-121. (canceled)

### Claim 122

A method of treating a subject having Birdshot Chorioretinopathy (BSCR), the method comprising administering to the subject an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitory nucleic acid molecule and an HLA-A29 inhibitory nucleic acid molecule.

### Claim 123

A method of treating a subject having Birdshot Chorioretinopathy (BSCR), the method comprising:
performing or having performed an assay on a biological sample from the subject to determine whether the subject comprises:
i) an HLA-A29 allele; and
ii) a functional Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) protein or a nucleic acid molecule encoding a functional ERAP2 protein; and
administering to the subject a therapeutically effective amount of an ERAP2 inhibitory nucleic acid molecule and an HLA-A29 inhibitory nucleic acid molecule to the subject having the functional ERAP2 protein or the nucleic acid molecule encoding a functional ERAP2 protein, and having the HLA-A29 allele,
wherein the presence of the HLA-A29 allele and the functional ERAP2 protein or the nucleic acid molecule encoding a functional ERAP2 protein, indicates that the subject is a candidate for treating the BSCR by inhibiting ERAP2 and HLA-A29.
